Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond
Human epidermal growth factor receptor 2 was the first successful molecular target in treating gastric cancer, marking a significant milestone for targeted therapies. Emerging evidence on Claudin18.2 (CLDN18.2) has recently reshaped the paradigm of therapeutic targets, expanding the focus beyond con...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251344804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Human epidermal growth factor receptor 2 was the first successful molecular target in treating gastric cancer, marking a significant milestone for targeted therapies. Emerging evidence on Claudin18.2 (CLDN18.2) has recently reshaped the paradigm of therapeutic targets, expanding the focus beyond conventional oncogenic drivers. Therapeutic strategies now target tumor-associated molecules which highly expressed in tumors but are not necessarily critical for tumor growth or survival. Molecules such as trophoblast cell surface antigen 2, Caprin-1, and Nectin-4 are promising non-oncogenic targets for advanced gastric cancer treatment. Innovative therapeutic approaches, such as antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapy, have accelerated the potential of targeting tissue-associated antigens. This review provides an update on CLDN18.2-directed therapies and explores the development of novel therapeutic strategies targeting non-oncogenic drivers. In addition, we discuss ongoing challenges, including biomarker overlap, resistance mechanisms, and future directions for next-generation molecular targeted therapy in gastric cancer. |
|---|---|
| ISSN: | 1758-8359 |